Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$20.98 +0.5%	$20.39	$13.40 ▼ $25.23	$3.51B	0.64	1.97 million shs	909,335 shs
ASND Ascendis Pharma A/S	$170.43 -3.2%	$167.90	$111.09 ▼ $183.00	$10.42B	0.38	500,851 shs	300,373 shs
IONS Ionis Pharmaceuticals	$41.51 -0.6%	$35.48	$23.95 ▼ $52.34	$6.61B	0.23	1.61 million shs	979,629 shs
SDGR Schrodinger	$21.43 +3.9%	$22.56	$16.60 ▼ $28.47	$1.57B	1.58	913,471 shs	527,205 shs
UTHR United Therapeutics	$295.18 +1.6%	$301.08	$266.98 ▼ $417.82	$13.32B	0.53	502,406 shs	245,806 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	-0.33%	-3.20%	-5.00%	+48.09%	+29.45%
ASND Ascendis Pharma A/S	+1.10%	+1.96%	+1.69%	+28.07%	+29.58%
IONS Ionis Pharmaceuticals	-2.79%	+5.75%	+18.39%	+63.78%	-9.35%
SDGR Schrodinger	-1.57%	+2.53%	-16.21%	+14.80%	-0.39%
UTHR United Therapeutics	-1.42%	+1.06%	-10.87%	+3.83%	-7.68%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	4.6784 of 5 stars	4.4	3.0	0.0	3.2	4.2	2.5
ASND Ascendis Pharma A/S	3.5704 of 5 stars	4.5	3.0	0.0	2.5	1.7	0.6
IONS Ionis Pharmaceuticals	4.6576 of 5 stars	4.4	2.0	3.0	3.3	3.3	0.6
SDGR Schrodinger	2.7962 of 5 stars	3.4	2.0	0.0	3.0	2.5	0.6
UTHR United Therapeutics	4.9946 of 5 stars	4.3	5.0	4.6	3.0	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.71	Moderate Buy	$27.88	32.86% Upside
ASND Ascendis Pharma A/S	3.00	Buy	$220.67	29.48% Upside
IONS Ionis Pharmaceuticals	2.78	Moderate Buy	$58.25	40.33% Upside
SDGR Schrodinger	2.75	Moderate Buy	$33.25	55.16% Upside
UTHR United Therapeutics	2.69	Moderate Buy	$384.62	30.30% Upside

Current Analyst Ratings Breakdown

Latest ACAD, UTHR, SDGR, IONS, and ASND Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	UTHR United Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$350.00 ➝ $330.00
7/3/2025	ASND Ascendis Pharma A/S	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$250.00
7/3/2025	SDGR Schrodinger	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$28.00
7/1/2025	IONS Ionis Pharmaceuticals	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Equal Weight ➝ Overweight	$51.00 ➝ $57.00
6/30/2025	UTHR United Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$410.00 ➝ $385.00
6/26/2025	ACAD ACADIA Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform	$19.00 ➝ $22.00
6/26/2025	ACAD ACADIA Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$37.00
6/26/2025	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/26/2025	ACAD ACADIA Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00
6/26/2025	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
6/23/2025	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$26.00 ➝ $38.00

(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$957.80M	3.67	$0.71 per share	29.72	$4.40 per share	4.77
ASND Ascendis Pharma A/S	$393.54M	26.47	N/A	N/A	($1.88) per share	-90.65
IONS Ionis Pharmaceuticals	$717.25M	9.21	N/A	N/A	$3.73 per share	11.13
SDGR Schrodinger	$207.54M	7.58	N/A	N/A	$5.78 per share	3.71
UTHR United Therapeutics	$2.88B	4.63	$28.46 per share	10.37	$144.34 per share	2.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$226.45M	$1.37	15.31	27.61	4.51	22.97%	17.46%	10.75%	8/5/2025 (Estimated)
ASND Ascendis Pharma A/S	-$409.12M	-$6.28	N/A	710.13	N/A	-93.22%	N/A	-33.29%	9/2/2025 (Estimated)
IONS Ionis Pharmaceuticals	-$453.90M	-$2.99	N/A	N/A	N/A	-63.65%	-91.85%	-15.77%	7/30/2025 (Estimated)
SDGR Schrodinger	-$187.12M	-$2.63	N/A	N/A	N/A	-83.39%	-44.74%	-26.29%	7/30/2025 (Estimated)
UTHR United Therapeutics	$1.20B	$25.06	11.78	10.74	6.45	40.44%	19.33%	16.73%	7/30/2025 (Estimated)

Latest ACAD, UTHR, SDGR, IONS, and ASND Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	ACAD ACADIA Pharmaceuticals	$0.14	N/A	N/A	N/A	$263.07 million	N/A
7/30/2025	Q2 2025	SDGR Schrodinger	-$0.83	N/A	N/A	N/A	$52.03 million	N/A
7/30/2025	Q2 2025	UTHR United Therapeutics	$6.89	N/A	N/A	N/A	$802.13 million	N/A
5/7/2025	Q1 2025	ACAD ACADIA Pharmaceuticals	$0.10	$0.11	+$0.01	$0.11	$239.32 million	$244.32 million
5/7/2025	Q1 2025	SDGR Schrodinger	-$0.81	-$0.82	-$0.01	-$0.82	$54.60 million	$59.55 million
5/1/2025	Q1 2025	ASND Ascendis Pharma A/S	-$1.56	-$1.66	-$0.10	-$1.66	$98.56 million	$123.97 million
4/30/2025	Q1 2025	IONS Ionis Pharmaceuticals	-$1.07	-$0.93	+$0.14	-$0.93	$144.31 million	$132.00 million
4/30/2025	Q1 2025	UTHR United Therapeutics	$6.29	$6.63	+$0.34	$6.63	$726.82 million	$794.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ASND Ascendis Pharma A/S	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
SDGR Schrodinger	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.88	2.80
ASND Ascendis Pharma A/S	N/A	1.04	0.71
IONS Ionis Pharmaceuticals	2.63	9.66	9.62
SDGR Schrodinger	N/A	3.45	3.45
UTHR United Therapeutics	N/A	5.46	5.23

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
ASND Ascendis Pharma A/S	N/A
IONS Ionis Pharmaceuticals	93.86%
SDGR Schrodinger	79.05%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	28.30%
ASND Ascendis Pharma A/S	40.00%
IONS Ionis Pharmaceuticals	2.60%
SDGR Schrodinger	8.60%
UTHR United Therapeutics	10.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	167.36 million	120.00 million	Optionable
ASND Ascendis Pharma A/S	1,017	61.13 million	36.68 million	Optionable
IONS Ionis Pharmaceuticals	1,069	159.16 million	154.85 million	Optionable
SDGR Schrodinger	790	73.38 million	67.07 million	Optionable
UTHR United Therapeutics	1,305	45.11 million	40.46 million	Optionable

ACAD, UTHR, SDGR, IONS, and ASND Headlines

Recent News About These Companies

United Therapeutics (NASDAQ:UTHR) Price Target Cut to $330.00 by Analysts at JPMorgan Chase & Co.

4 hours ago | marketbeat.com

Brookstone Capital Management Makes New $1.48 Million Investment in United Therapeutics Corporation (NASDAQ:UTHR)

July 7 at 5:06 AM | marketbeat.com

Will United Therapeutics (UTHR) Beat Estimates Again in Its Next Earnings Report?

July 4, 2025 | zacks.com

New York State Teachers Retirement System Lowers Holdings in United Therapeutics Corporation (NASDAQ:UTHR)

July 3, 2025 | marketbeat.com

United Therapeutics Corporation (NASDAQ:UTHR) Holdings Raised by Sumitomo Mitsui Trust Group Inc.

July 3, 2025 | marketbeat.com

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

July 2, 2025 | zacks.com

Amalgamated Bank Trims Position in United Therapeutics Corporation (NASDAQ:UTHR)

July 2, 2025 | marketbeat.com

Allspring Global Investments Holdings LLC Decreases Stock Holdings in United Therapeutics Corporation (NASDAQ:UTHR)

July 2, 2025 | marketbeat.com

Wealth Enhancement Advisory Services LLC Sells 2,214 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

July 2, 2025 | marketbeat.com

Diversified Trust Co Purchases 1,074 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

July 1, 2025 | marketbeat.com

Bessemer Group Inc. Cuts Stock Position in United Therapeutics Corporation (NASDAQ:UTHR)

July 1, 2025 | marketbeat.com

Cambridge Investment Research Advisors Inc. Purchases 2,211 Shares of United Therapeutics Corporation (NASDAQ:UTHR)

July 1, 2025 | marketbeat.com

UBS Group Cuts United Therapeutics (NASDAQ:UTHR) Price Target to $385.00

June 30, 2025 | marketbeat.com

United Therapeutics’ Inhaled Treprostinil Study: A Potential Game-Changer for IPF Treatment

June 30, 2025 | tipranks.com

KBC Group NV Has $33.63 Million Position in United Therapeutics Corporation (NASDAQ:UTHR)

June 30, 2025 | marketbeat.com

Paul A. Mahon Sells 11,000 Shares of United Therapeutics Corporation (NASDAQ:UTHR) Stock

June 29, 2025 | americanbankingnews.com

United Therapeutics Corporation (UTHR) - Yahoo Finance

June 28, 2025 | finance.yahoo.com

United Therapeutics Corporation (NASDAQ:UTHR) EVP Paul A. Mahon Sells 11,000 Shares

June 28, 2025 | insidertrades.com

United Therapeutics Announces World’s First Bioengineered External Liver Treatment in Clinical Study

June 28, 2025 | msn.com

UTHR United Therapeutics Corporation - Seeking Alpha

June 27, 2025 | seekingalpha.com

Insider Selling: United Therapeutics Corporation (NASDAQ:UTHR) EVP Sells 11,000 Shares of Stock

June 27, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!
By Thomas Hughes | June 16, 2025
View AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!
Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst
By Thomas Hughes | June 26, 2025
View Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst
2 Under the Radar Space & Defense Stocks With Huge Potential
By Leo Miller | July 1, 2025
View 2 Under the Radar Space & Defense Stocks With Huge Potential
As Oil Prices Rebound, These Stocks Could Fuel the Next Rally
By Sarah Horvath | June 9, 2025
View As Oil Prices Rebound, These Stocks Could Fuel the Next Rally

ACAD, UTHR, SDGR, IONS, and ASND Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$20.98 +0.10 (+0.48%)

As of 02:51 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Ascendis Pharma A/S NASDAQ:ASND

$170.43 -5.55 (-3.15%)

As of 02:49 PM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Ionis Pharmaceuticals NASDAQ:IONS

$41.51 -0.27 (-0.65%)

As of 02:52 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Schrodinger NASDAQ:SDGR

$21.43 +0.80 (+3.88%)

As of 02:52 PM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

United Therapeutics NASDAQ:UTHR

$295.18 +4.79 (+1.65%)

As of 02:57 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time